Is Your Pharmacy Ready to Sell? Here's What Buyers Will Scrutinize First

Gather federal tax returns, internally prepared P&Ls, and monthly revenue breakdowns segmented by payer type (Medicare Part D, Medicaid, commercial PBMs, cash) and drug category (brand, generic, specialty, compounded). Buyers will normalize EBITDA by removing owner compensation above market rate, personal vehicle expenses, and one-time costs, so having clean, segmented financials accelerates this process and reduces buyer skepticism.

Export prescription count data from your pharmacy management system (PioneerRx, QS/1, Liberty, etc.) showing total prescriptions dispensed, active patient count, and 30-day refill rate trends over the past three years. Buyers treat declining prescription volume as a red flag that directly reduces earnout potential and file value. Stable or growing volume is one of the strongest valuation signals you can present.

Pull DIR fee recoupments from each PBM reconciliation report for the past two years and calculate your true net reimbursement per prescription after DIR adjustments. Buyers will request this detail during due diligence and will discount valuations significantly if DIR exposure is high and undisclosed. Presenting this proactively demonstrates transparency and allows you to frame it accurately rather than letting buyers draw worst-case conclusions.

Work with your CPA to recast your P&L with a market-rate pharmacist salary in place of owner draws, and remove non-recurring expenses such as one-time equipment purchases, legal fees, or personal benefits run through the business. This recasted EBITDA is the figure buyers and SBA lenders will use to size their offers and debt coverage ratios — it is the single most important number in your sale.

Produce a detailed prescription file report from your pharmacy management system showing total active patients (filled at least one prescription in the past 12 months), average prescriptions per patient per year, top 20 drug categories by volume, and 30-day refill adherence rates. This report is the foundation of prescription file valuation — buyers and their advisors will scrutinize it closely to assess patient retention risk and recurring revenue quality.

Isolate revenue from compounding services, long-term care facility contracts, hospice accounts, or specialty drug dispensing and document it separately from standard retail PBM revenue. This revenue commands higher margins and is less exposed to PBM reimbursement compression, making it a significant valuation driver. Buyers — especially PE-backed platforms focused on specialty and compounding roll-ups — will pay a meaningful premium for these revenue streams.

Honestly assess how many of your most loyal patients have a strong personal relationship with you as the owner-pharmacist rather than with your staff or location. If significant prescription volume walks out the door with you at closing, buyers will structure aggressive earnouts or reduce their upfront offer. Identify these patients and begin transitioning them to staff pharmacists or other relationship touchpoints 12–18 months before your target close date.

Compile revenue from medication therapy management programs, immunization clinics, point-of-care testing, and any other clinical services your pharmacy provides. These services demonstrate clinical capability that differentiates you from mail-order competition, increases patient stickiness, and adds incremental revenue that buyers value beyond the prescription file alone.

Verify your DEA registration is active, fully paid, and free of any pending investigations or consent agreements. Contact the DEA Diversion Field Office for your region to understand the current change-of-ownership process — buyers typically must obtain a new DEA registration rather than transfer yours, which requires advance planning. Any history of DEA audits, Schedule II discrepancies, or controlled substance violations must be disclosed and will be investigated thoroughly by buyers and their attorneys.

Contact your state board of pharmacy to confirm your pharmacy permit is current, in good standing, and to understand the new owner application and inspection process required in your state. Some states require a physical inspection of the pharmacy before a new permit is issued, which can add 30–90 days to closing timelines. Buyers and their attorneys will request a copy of your current permit and any correspondence with the state board as part of standard due diligence.

Pull every active PBM provider agreement — Medicare Part D networks, Medicaid managed care contracts, commercial PBM agreements — and review the change-of-ownership, assignment, and termination clauses in each. Some PBM contracts require prior written notice or approval before a sale closes; others may allow termination upon change of ownership. Buyers must understand which networks the new owner can inherit versus which require fresh credentialing, and this process takes time.

Identify any open or recently closed investigations, audit demand letters from PBMs, or CMS compliance findings and work with your pharmacy attorney and compliance consultant to resolve them before going to market. Buyers will perform compliance background checks and any unresolved issues will either kill the deal or dramatically reduce the offer price. Sellers who disclose resolved issues with documentation of remediation are in a far stronger position than those who surface problems during buyer due diligence.

Create a staffing roster listing every licensed pharmacist and pharmacy technician, including their license numbers, expiration dates, certifications (e.g., immunization, MTM, compounding), and employment status. Buyers — especially those financing with SBA loans — need to verify that the pharmacy can operate independently without the selling owner from day one of the transition. A licensed pharmacist willing to remain post-close is a significant value driver; an owner-only operation with no successor pharmacist is a serious liability.

Perform a physical inventory count of all drug stock and document your valuation methodology — most pharmacy transactions price inventory at cost (acquisition cost) and add it on top of the enterprise value at closing. Use your wholesaler invoice data (McKesson, AmerisourceBergen, Cardinal Health) to document average acquisition cost by item. Buyers will hire a third-party inventory counting service at or just before closing; your pre-count gives you a baseline to validate their figures and avoid last-minute disputes.

Pull your commercial lease and review the assignment, sublease, and change-of-ownership clauses. Buyers — and SBA lenders — require a lease with sufficient remaining term, typically at least 3–5 years remaining or renewable, to justify the acquisition. If your lease is short-term, expiring, or contains landlord consent requirements for assignment, address this with your landlord well before going to market. A favorable, assignable long-term lease is a material asset; a lease expiring in 12 months is a liability.

Compile your primary drug wholesaler agreement, any generic purchasing programs (e.g., through PSAO or buying group membership), and preferred vendor contracts for durable medical equipment or compounding supplies. Buyers want to understand your cost-of-goods structure and whether favorable purchasing arrangements are transferable. PSAO membership and its transferability should be confirmed directly with the PSAO.

Compile written SOPs covering dispensing workflow, controlled substance handling, HIPAA compliance procedures, point-of-sale processes, third-party billing and reconciliation, and staff supervision protocols. Operational documentation demonstrates to buyers — particularly first-time ownership pharmacists — that the business runs on systems, not solely on your personal expertise. This is especially important if you plan to exit fully within 12 months of closing.

Hire an M&A advisor or business broker with documented pharmacy transaction experience — not a generalist business broker who also sells restaurants and auto shops. A pharmacy-specialized advisor will properly value your prescription file, understand PBM contract nuances, qualify pharmacist-buyers for licensure and financial capability simultaneously, and manage the DEA and state board coordination that general brokers routinely botch. Their fee is typically 8–12% of the sale price for smaller transactions but is almost always recovered through higher final valuations and smoother closings.

Work with your advisor to develop a CIM that presents your pharmacy's financial performance, prescription file metrics, specialty or compounding revenue, compliance history, staff capabilities, and growth opportunities in a clear and compelling format. The CIM is the document that qualified buyers will use to decide whether to submit a letter of intent — a strong CIM positions your pharmacy as a premium asset and attracts more competitive offers.

Clarify internally — and communicate to your advisor — how much you are willing to carry in seller financing, whether you are open to an earnout tied to prescription volume retention, how long you are willing to remain as a consultant post-close (typically 3–12 months for pharmacies), and whether you prefer an asset sale or stock sale from a tax perspective. These decisions directly shape which buyers are the right fit and how offers will be structured.

Work with your advisor to identify whether your pharmacy is best suited for a first-time pharmacist buyer using SBA 7(a) financing, an existing independent pharmacy operator seeking geographic expansion, or a private equity-backed compounding or specialty platform. Each buyer type has different valuation frameworks, due diligence timelines, and deal structure preferences. Marketing to the right buyer pool from the start prevents wasted time with unqualified prospects and gets you to a close faster.